COVID-19

Vanderbilt University Medical Center has a new weapon in the fight against COVID-19 — an investigational antibody treatment approved last month for emergency use in COVID-19 outpatients at high risk of developing severe disease or requiring hospital care.

This spring in the U.S., there were widespread delays in elective health care procedures and screenings. Hospitals, in observance of federal guidelines, were, for a time, conserving beds and protective equipment in preparation for a surge in COVID-19 admissions. And, perhaps on a more prolonged basis, patients in many areas of the country stayed away due to anxiety over catching COVID-19 from other patients or their health care team.

The development of the vaccines, monoclonal antibodies and antiviral drugs that ultimately will defeat COVID-19 wouldn’t have been possible had it not been for the unflagging and selfless efforts of a global army of research nurses, laboratory personnel, recruiters and other staff.

In March, Vanderbilt University Medical Center leaders established a command center on campus to address the myriad issues that the Medical Center would face in the coming days, weeks and months as the COVID-19 pandemic encroached on Tennessee, then Nashville and finally on campus.

“It’s a tradition for us as well as for the Medical Center. We wanted to bring that same holiday cheer this year.”

Vanderbilt LifeFlight has transported more than 220 Covid-19 patients since the pandemic started with the numbers rising dramatically in the last few weeks.

COVID-19 has been linked to cases of new-onset diabetes, diabetes-related emergencies and a higher death rate among diabetes patients.